What Is Aspergillus Fumigatus? All About The Deadly Fungus Spreading In US
A dangerous fungus called Aspergillus fumigatus is rapidly spreading throughout the United States.
A dangerous fungus is making headlines in the US for its alarming ability to invade the human body and destroy tissue from within. Identified as Aspergillus fumigatus, this fast-spreading pathogen has scientists concerned, especially as warmer temperatures could accelerate its growth.
What Is This Deadly Fungus And How Can You Stay Safe From It? Here's What You Need To Know
Aspergillus fumigatus is a fungus that spreads through the air, releasing microscopic spores known as conidia. These spores are so small that people often inhale them unknowingly. Common in the environment, this fungus can be found in soil, decaying plants, and even household dust.
The National Library of Medicine notes that it grows best at around 37°C and can thrive in warm, moist settings. Remarkably, it can even survive in compost piles at temperatures exceeding 120°F for extended periods.
While most individuals' immune systems can fight off the spores without issue, some people, especially those with weakened immunity, can develop a severe lung condition known as aspergillosis. In extreme cases, this infection can progress to organ failure and become fatal.
Who Could Become Infected?
Reportedly, those most vulnerable to infection include individuals with weakened immune systems. This includes people undergoing cancer treatment, those with asthma or HIV, individuals with low white blood cell counts, and those recovering from recent illnesses like the flu.
Health officials note that tracking the fungus is challenging, as aspergillosis is not a reportable disease – its cases, hospitalisations and deaths aren't officially recorded.
Around 40,000 cases progress into chronic pulmonary aspergillosis, a long-lasting lung infection. Though invasive aspergillosis is rare, it poses a greater threat by spreading from the lungs to organs like the brain, heart and kidneys.
How To Stay Safe From Aspergillus Fumigatus Infection
To reduce the risk of infection, doctors are said to have recommended that people with weakened immune systems steer clear of soil, gardening, and environments with mould.
It's also advised to wear masks in dusty places and ensure clean, filtered air, especially in hospitals and at home. In response, hospitals in affected states have already started conducting mould inspections and implementing antifungal safety protocols.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
2 hours ago
- Hindustan Times
As cases rise, Meghalaya says it may mandate HIV/AIDS testing before marriage
SHILLONG: Meghalaya health minister Ampareen Lyngdoh on Thursday said the state could make pre-marital testing for HIV mandatory across the state as one of the steps to curb the rising incidence of HIV/AIDS. Ampareen Lyngdoh said HIV/AIDS cases in East Khasi Hills alone have doubled to 3,432, but only 1,581 patients were under treatment (X/ampareenlyngdoh) 'We are mentally prepared to take strong actions,' Lyngdoh said after a meeting chaired by deputy chief minister Prestone Tynsong and eight legislators from the East Khasi Hills to discuss the rising cases of HIV in their constituencies. 'The numbers are scary. And it's time Meghalaya takes the monster by its neck,' Lyngdoh declared. Lyngdoh said HIV/AIDS cases in East Khasi Hills alone have doubled to 3,432, but only 1,581 patients were under treatment. She added that 681 patients hadn't turned up for follow-ups, raising red flags over the state's ability to retain patients within the treatment net. 'Today, we discussed only East Khasi Hills. But the most alarming numbers are actually from West and East Jaiñtia Hills. The virus is no longer a threat—it's a full-blown crisis,' she warned. The minister said the government would refrain from disclosing location-specific data to prevent stigma but confirmed that Meghalaya's HIV/AIDS burden has reached critical levels. In this context, she said the government was seriously considering making HIV testing compulsory before marriage. 'If Goa can do it, why can't Meghalaya?' Lyngdoh asked, adding that the state may introduce laws for the community's well-being. Lyngdoh said they would now sit with legal experts and the department to see how legislation of this nature can be framed. We're no longer in denial,' the minister said. To be sure, Goa - like Maharashtra and Andhra Pradesh – has debated the idea of mandating pre-marital testing for nearly two decades but has not enacted a law. For one, it has been argued that mandating testing before marriage would have limited utility if people were having pre-marital sex. UNAIDS and WHO also strongly oppose mandatory or compulsory HIV testing and advocate for voluntary, confidential testing with informed consent. Lyngdoh said the challenge also lies in ramping up testing and ensuring access to Antiretroviral Therapy (ART). Citing government data, Lyngdoh revealed that 159 patients have died after dropping out of ART treatment, which she called an 'unacceptable' figure. 'HIV/AIDS is not a death sentence. It is manageable like cancer or TB—there's a clear treatment protocol. We just need people to come forward,' she said. However, a large number of people remain reluctant to get tested, which hinders surveillance and treatment efforts. 'There are likely many more in our communities who remain undiagnosed. That's the scariest part,' she cautioned. The minister said unlike other states, Meghalaya hadn't been able to identify the population of injecting drug users. 'That tells us our testing and tracking systems need urgent overhaul,' Lyngdoh said. The government plans to hold region-wise consultations across Garo Hills and Jaiñtia Hills, involving senior doctors and bureaucrats, before finalising a new policy. The policy blueprint, once prepared, will be brought before the cabinet.
The Hindu
7 hours ago
- The Hindu
All you need to know about: sarcoidosis
Sarcoidosis is an inflammatory condition that can affect several organs. A disease of unknown etiology or chronic inflammation can lead to permanent scarring of the affected tissues. Considered a rare disease, research is ongoing to understand further the causes, diagnosis and treatment modalities. What is sarcoidosis? Sarcoidosis is believed to be an exaggerated response of the immune system either due to a genetic disposition or due to environmental triggers. It results in affected people developing lumps on their skin or in other parts of the body. The Mayo Clinic website describes the lumps or clusters of immunity cells in an organ as 'tiny collections of immune system cells in any part of the body,' which are red, swollen lumps called granulomas. They commonly occur in lungs and the lymph nodes of the chest, the website adds. What are the symptoms? Persons with sarcoidosis may suffer from a variety of symptoms including fatigue, shortness of breath, wheezing, chronic cough, skin rashes that appear scaly, red eyes, irregular heart beat, weakness or numbness of a limb or part of face, discolouration of the nose, cheek, lips or ears; and chest pain. Some people may remain symptom free as the disease disappears on its own but in some others, though the disease may not progress they may have symptoms that affect their lifestyle. A third of those diagnosed with the condition may require long-term treatment. A person in whom the disease has been active for over two to five years is termed to have a chronic ailment. In such persons, it can be life-threatening. How rare is the condition? In the United States of America an estimated 1.5 to 2 lakh persons live with sarcoidosis. The National Library of Medicine, operated by the United States government, states that the incidence of sarcoidosis is 11 in 1 lakh among the white population and 34 in 1 lakh among the African American population. Across the world an estimated 1.2 million have the condition. In a letter published in 2019 in the Sarcoidosis, Vasculitis and Diffuse Lung Diseases journal, researchers from the All India Institute of Medical Sciences, New Delhi, stated that while the reported prevalence of sarcoidosis in India was estimated to be 10-12 cases per 1,000 new registrations in a respiratory unit at Kolkata and 61.2/100,000 new cases at a centre in New Delhi, 'these figures are unlikely to be a true representation as sarcoidosis is usually unidentified due to the high burden of tuberculosis here. Real figures are anticipated to be much higher.' At AIIMS, Delhi, approximately 100 new cases of pulmonary sarcoidosis are being diagnosed every year, says Rashi Jain, of the department of pulmonary medicine and sleep disorders at AIIMS, Delhi and the main author of the letter. 'The number is quite noticeable for a disease otherwise considered rare,' the letter noted. Organisations working to raise awareness about the disease say approximately five to 10% of all those diagnosed will have advanced sarcoidosis. What are the treatment modalities? Research studies and patient advocate organisations have all called for more research on sarcoidosis to develop effective treatment strategies. Dr. Jain says low awareness about sarcoidosis in India results in doctors misdiagnosing it as tuberculosis. Stating that the condition could cause mental stress due to the multiple evaluations and tests required, she called for exclusive clinics with a multidisciplinary teams of healthcare workers from various specialties, to treat patients with sarcoidosis. Among the affected, around 25% to 30% develop extrapulmonary sarcoid. While in men the heart function is commonly affected, in women, the skin and eyes are more prominently affected. Many persons with the disease recover completely. In those with advanced sarcoidosis (active disease for over two to five years), treatment options include corticosteroids besides other therapies. Persons who require treatment even if they do not have symptoms are also classified as having advanced sarcoidosis. Persons on advanced treatment also need to contend with fatigue, pain, cognitive failure, neuropathy, an inability to exercise and depression besides other comorbidities such as diabetes and high blood pressure.
Hindustan Times
7 hours ago
- Hindustan Times
How AI, biosensing and economic modelling are shaping globally scalable health care solutions
In the digital age, health innovation is no longer confined to the sterile boundaries of laboratories or the corridors of hospitals. A quiet revolution is underway—one that brings together the precision of artificial intelligence, the responsiveness of biosensing technology, and the foresight of economic analytics. This powerful convergence is not only redefining diagnostics but is also making health care smarter, faster, and more globally adaptable. AI(Getty Images/iStockphoto) At the heart of this transformation is a multidisciplinary approach that dissolves traditional silos between technology, medicine, and economics. By integrating wearable biosensors with edge AI and predictive modelling, emerging platforms like Lakshmi Kalyani Chinthala's HIVSense-Econ are not just detecting diseases—they are mapping out their ripple effects on human productivity, public resources, and long-term economic health. The foundation of this innovation lies in biosensing—a technology that captures physiological data directly from the human body. Miniaturised, non-invasive sensors can now track vital signs, immune responses, and even specific biomarkers for diseases like HIV. However, it's not the sensors alone that make the difference; it's what happens next. Edge AI processing—artificial intelligence deployed at or near the data source—analyses incoming signals in real time. This eliminates delays associated with cloud-based systems and enables on-the-spot interpretation. Combined, these technologies give health care providers the ability to detect illnesses not just early, but immediately, allowing for more precise intervention. What makes Chinthala's model uniquely powerful is its embrace of predictive economics. Health care has often been reactive—focused on treatment after the fact. But what if we could project the economic cost of an outbreak before it happens? What if decision-makers could calculate how a surge in illness might affect workforce productivity, insurance premiums, or public welfare budgets? By embedding economic algorithms into diagnostic platforms, predictive tools can now forecast potential financial losses tied to health trends. This is particularly vital for governments managing strained public health resources, for companies aiming to ensure workforce stability, and for NGOs responding to vulnerable communities. This economic layer also promotes preventative investment. If a system like HIVSense-Econ warns of a likely spike in HIV infections in a particular region, targeted resources can be deployed in advance. This saves not only lives, but funds—redirecting money from expensive crisis response towards sustainable prevention. Perhaps the most compelling aspect of this technological integration is its versatility across different environments. In high-income nations, such platforms can plug into enterprise health systems or insurance analytics. In lower-income or resource-constrained settings, the same system can operate through low-power devices, bringing cutting-edge predictive health care to the last mile. This kind of scalability is rare. Too often, health care technologies are designed with a single demographic or geographic context in mind. By contrast, tools that are adaptable—technically lightweight, cost-efficient, and intuitively designed—are the ones most likely to bridge global disparities in health care access. The convergence of biosensing, AI, and economic forecasting marks a shift towards more human-centred and sustainable health systems. It empowers policymakers with data, equips clinicians with real-time insights, and gives communities the foresight to act before problems become emergencies. As innovators like Chinthala continue to expand the reach of such platforms, the line between health diagnostics and economic planning will become increasingly blurred—for the better. We are witnessing not just an upgrade in medical technology, but a reimagination of public health itself: one that is predictive, participatory, and profoundly global. This article is authored by Dr. Olga, managing director, Ambisphere Research Laboratory.
